Angiotensin-neprilysin inhibition versus enalapril in heart failure
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients. METHODS: In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes. RESULTS: The trial was stopped early, according to prespecified rules, after a median follow-up of 27 months, because the boundary for an overwhelming benefit with LCZ696 had been crossed. At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P<0.001). A total of 711 patients (17.0%) receiving LCZ696 and 835 patients (19.8%) receiving enalapril died (hazard ratio for death from any cause, 0.84; 95% CI, 0.76 to 0.93; P<0.001); of these patients, 558 (13.3%) and 693 (16.5%), respectively, died from cardiovascular causes (hazard ratio, 0.80; 95% CI, 0.71 to 0.89; P<0.001). As compared with enalapril, LCZ696 also reduced the risk of hospitalization for heart failure by 21% (P<0.001) and decreased the symptoms and physical limitations of heart failure (P=0.001). The LCZ696 group had higher proportions of patients with hypotension and nonserious angioedema but lower proportions with renal impairment, hyperkalemia, and cough than the enalapril group. CONCLUSIONS: LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“showed superior efficacy of ARNI therapy over enalapril in chronic HF patients already receiving maximally tolerated dose of a renin-angiotensin system inhibitor (RASi).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [5]
In the citing paper
“Neprilysin inhibition does not seem to add to this effect.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [224]
In the citing paper
“Neprilysin inhibition needs to be studied further, but does not seem to enhance this effect.224”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [224]
In the citing paper
“The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30-40% of patients)”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [31]
In the citing paper
“In clinical trials of chronic HF patients, the prevalence of T2DM was around 30%, irrespective of HF phenotype (i.e.HFrEF and HFpEF) (Table 3).31 -48”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [31]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
(1999) · The Lancet · doi:10.1016/s0140-6736(98)11181-9 · Cited by 4,929
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citationA Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Cited by
Items 401–500 of 1,026
Bradykinin: Inflammatory Product of the Coagulation System
Hofman, Z. L. M., de Maat, S., Hack, C. E., & Maas, C. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-016-8540-0 · Cited by 112
“During clinical trials of NEP inhibitors [28], up to 2.”
Ferreira, J. P., Duarte, K., Graves, T., Zile, M. R., Abraham, W. T., Weaver, F. A., Lindenfeld, J. M., & Zannad, F. M. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.09.936 · Cited by 109
Self-citationParizo, J. T., Goldhaber-Fiebert, J. D., Salomon, J. A., Khush, K. K., Spertus, J. A., Heidenreich, P. A., & Sandhu, A. T. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.1437 · Cited by 107
Practical guidance on the use of sacubitril/valsartan for heart failure
Sauer, A. J., Cole, R. T., Jensen, B. C., Pal, J. D., Sharma, N. C., Yehya, A., & Vader, J. M. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9757-1 · Cited by 126
“When trial data were used to generate actuarial estimates of outcomes for long-term treatment, the predicted benefit of sacubitril/valsartan rather than enalapril for a patient Table 1 Common AEs (≥ 2%) in the PARADIGM-HF trial during the double-blind treatment period [8] Preferred term, n (%) Sacubitril/valsartan, n…”
BackgroundMethodInfluentialInflammation and Circulating Natriuretic Peptide Levels
Fish-Trotter, H. L., Ferguson, J. F., Patel, N., Arora, P. K., Allen, N. B., Bachmann, K. N., Daniels, L. B., Reilly, M. P., Lima, J. A. C., Wang, T. J., et al. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.119.006570 · Cited by 119
Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure
Emdin, M., Aimo, A., Castiglione, V., Vergaro, G., Georgiopoulos, G. A., Saccaro, L. F., Lombardi, C., Passino, C., Cerbai, E., Metra, M., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.031 · Cited by 112
Care Gaps in Adherence to Heart Failure Guidelines
Jarjour, M., Henri, C., de Denus, S., Fortier, A., Bouabdallaoui, N., Nigam, A., O’Meara, E., Ahnadi, C., White, M., Garceau, P., et al. (2020) · JACC: Heart Failure · doi:10.1016/j.jchf.2020.04.019 · Cited by 105
Self-citationMurtaugh, C. M., Deb, P., Zhu, C., Peng, T. R., Barrón, Y., Shah, S., Moore, S. M., Bowles, K. H., Kalman, J., Feldman, P. H., et al. (2017) · Health Services Research · doi:10.1111/1475-6773.12537 · Cited by 104
“…treatment of HF patients could restrain growth over time depending on whether the results of the clinical trial—which enrolled a predominantly male, relatively young sample of patients with reduced ejection fraction—are achieved in real-world Medicare beneficiary practice (McMurray et al. 2014).”
BackgroundTargeting the apelin system for the treatment of cardiovascular diseases
Chapman, F. A., Maguire, J. J., Newby, D. E., Davenport, A. P., & Dhaun, N. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad171 · Cited by 104
“108 As neprilysin fully inactivates apelin peptides, the success of these agents might be partly due to an increase in apelin peptide levels and this warrants further investigation in clinical studies.”
BackgroundHeart Failure Outcomes in Clinical Trials of Glucose-Lowering Agents in Patients with Diabetes
Fitchett, D. H., Udell, J. A., & Inzucchi, S. E. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.633 · Cited by 102
Fonarow, G. C., Hernandez, A. F., Solomon, S. D., & Yancy, C. W. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.1724 · Cited by 105
Self-citationNovel heart failure biomarkers: why do we fail to exploit their potential?
Piek, A., Du, W., de Boer, R. A., & Silljé, H. H. W. (2018) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2018.1460576 · Cited by 114
“Importantly, with the positive results of clinical HF trials with entresto (LCZ-696) [33,34], the introduction of this drug in daily clinical HF practice will make the interpretation of BNP levels in such treated patients more difficult.”
BackgroundIncome Inequality and Outcomes in Heart Failure
Dewan, P., Rørth, R., Jhund, P. S., Ferreira, J. P., Zannad, F. M., Shen, L., Køber, L., Abraham, W. T., Desai, A. S., Dickstein, K., et al. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2018.11.005 · Cited by 123
“The design, baseline characteristics, and outcomes of the PARADIGM-HF and ATMOSPHERE trials have been published and are briefly described here (8,9).”
MethodSelf-citationShen, L., Ramires, F. J. A., Martínez, F. A., Bodanese, L. C., Echeverría, L. E., Gómez, E. A., Abraham, W. T., Dickstein, K., Køber, L., Packer, M., et al. (2017) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.004361 · Cited by 118
Self-citationSimpson, J., Jhund, P. S., Lund, L. H., Padmanabhan, S., Claggett, B. L., Shen, L., Petrie, M. C., Abraham, W. T., Desai, A. S., Dickstein, K., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2019.5850 · Cited by 102
Self-citationCyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure
Kamel, R., Leroy, J., Vandecasteele, G., & Fischmeister, R. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00756-z · Cited by 110
Heart failure with preserved ejection fraction: Refocusing on diastole
Abbate, A., Arena, R. A., Abouzaki, N. A., Tassell, B. W. V., Canada, J. M., Shah, K. B., Biondi‐Zoccai, G., & Voelkel, N. F. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.11.106 · Cited by 108
Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases
Kokkonen, K., & Kass, D. A. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104756 · Cited by 100
Shaddy, R. E., Canter, C. E., Halnon, N. J., Kochilas, L. K., Rossano, J. W., Bonnet, D., Bush, C. A., Zhao, Z., Kantor, P. F., Burch, M., et al. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.07.006 · Cited by 105
“This study will be conducted in twoparts: Part 1, the dose determination study, will assess the pharmacokinetics (PK) and pharmacodynamics (PD) of sacubitril/valsartan following single ascending dose administration; and Part 2, the efficacy and safety study, will evaluate the superiority of sacubitril/valsartan over e…”
BackgroundResultInfluentialChange in renal function associated with drug treatment in heart failure: national guidance
Clark, A. L., Kalra, P. R., Petrie, M. C., Mark, P. B., Tomlinson, L. A., & Tomson, C. (2019) · Heart · doi:10.1136/heartjnl-2018-314158 · Cited by 114
Abraham, W. T., Psotka, M. A., Fiuzat, M., Filippatos, G. S., Lindenfeld, J. M., Mehran, R., Ambardekar, A. V., Carson, P. E., Jacob, R., Januzzi, J. L., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.10.002 · Cited by 123
Self-citationHeart failure in type 2 diabetes: current perspectives on screening, diagnosis and management
Ceriello, A., Catrinoiu, D., Chandramouli, C., Cosentino, F., Dombrowsky, A. C., Itzhak, B., Lalic, N. M., Prattichizzo, F., Schnell, O., Seferovic, P. M., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01408-1 · Cited by 123
“ARNI: The long-term blood pressure-lowering effect of sacubitril-valsartan (LCZ696), a dual-acting ARNI, was tested in the PARADIGM-HF trial, demonstrating that sacubitril-valsartan can significantly reduce the risk of both death and HHF in individuals with HFrEF in comparison to the ACE-I enalapril [110].”
BackgroundRecent Developments in Heart Failure
Dassanayaka, S., & Jones, S. P. (2015) · Circulation Research · doi:10.1161/circresaha.115.305765 · Cited by 117
Shun-Shin, M. J., Zheng, S. L., Cole, G. D., Howard, J. P., Whinnett, Z. I., & Francis, D. P. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx028 · Cited by 107
Natriuretic Peptides in Chronic Heart Failure
Rocca, H. B., & Wijk, S. S. (2019) · Cardiac failure review · doi:10.15420/cfr.2018.26.1 · Cited by 120
“A prominent recent example is the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial, which investigated the effect of sacubitril/valsartan compared to enalapril in chronic HFrEF.30 To meet the inclusion criteria, patients had to have a B…”
BackgroundInfluentialAccelerated and personalized therapy for heart failure with reduced ejection fraction
Shen, L., Jhund, P. S., Docherty, K. F., Vaduganathan, M., Petrie, M. C., Desai, A. S., Køber, L., Schou, M., Packer, M., Solomon, S. D., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac210 · Cited by 110
“Among patients taking the study drug, the mean (+SD) daily dose was 375+ 71 mg for sacubitril/valsartan at the final visit.(3) In DAPA-HF, 4744 patients with NYHA Classes II–IV symptoms and LVEF≤ 40%, with an elevated plasma natriuretic peptide level, were randomly assigned to either dapagliflozin (10 mg once daily) o…”
Self-citationSacubitril/valsartan: beyond natriuretic peptides
Singh, J. S. S., Burrell, L. M., Cherif, M., Squire, I. B., Clark, A. L., & Lang, C. C. (2017) · Heart · doi:10.1136/heartjnl-2017-311295 · Cited by 99
Yang, J., Zhao, W., & Chen, D. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.06.086 · Cited by 104
Savarese, G., Lindberg, F., Cannata, A. N., Chioncel, O. D., Stolfo, D., Musella, F., Tomasoni, D., Abdelhamid, M., Banerjee, D., Bayés‐Genís, A., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3295 · Cited by 114
Racial Differences in Natriuretic Peptide Levels
Gupta, D. K., de Lemos, J. A., Ayers, C. R., Berry, J. D., & Wang, T. J. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2015.02.008 · Cited by 108
“Recently, the PARADIGM-HF trial demonstrated that combined neprilysin and angiotensin inhibition was superior to angiotensin inhibition alone in reducing heart failure progression and cardiovascular death in patients with heart failure and reduced ejection fraction, supporting chronic enhancement of the natriuretic pe…”
BackgroundZile, M. R., Abraham, W. T., Weaver, F. A., Butter, C., Ducharme, A., Halbach, M., Klug, D., Lovett, E. G., Müller‐Ehmsen, J., Schafer, J. E., et al. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.299 · Cited by 102
Self-citationAnker, S. D., Schroeder, S., Atar, D., Bax, J. J., Ceconi, C., Cowie, M. R., Crisp, A., Dominjon, F., Ford, I., Ghofrani, H.-A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.516 · Cited by 97
Self-citationThe Future of Heart Failure Diagnosis, Therapy, and Management
Udelson, J. E., & Stevenson, L. W. (2016) · Circulation · doi:10.1161/circulationaha.116.023518 · Cited by 113
“ARB and a neprolysin inhibitor, promises to disrupt this stack of therapies.(18,19) First, this agent is anticipated to displace the cornerstone of ACEi/ARB, on top of which the other therapies have been tested.”
BackgroundResultChang, H., Feng, A.-N., Fong, M.-C., Hsueh, C.-W., Lai, W., Huang, K., Chong, E. Y., Chen, C.-N., Chang, H.-C., & Yin, W. (2019) · Journal of Cardiology · doi:10.1016/j.jjcc.2019.03.010 · Cited by 104
Law, J. P., Pickup, L. C., Pavlović, D., Townend, J., & Ferro, C. J. (2022) · Journal of Human Hypertension · doi:10.1038/s41371-022-00751-4 · Cited by 134
“Clinical studies have shown sacubitril/valsartan to reduce the risk of death and hospitalisation when compared to enalapril [239], and provide a further reduction to blood pressure versus valsartan alone [240].”
Background2024 EACTS Guidelines on perioperative medication in adult cardiac surgery
Jeppsson, A., (Sweden), (.-C., Rocca, B., (Italy), (.-C., Hansson, E. C., (Sweden), Guðbjartsson, T., (Iceland), James, S. K., (Sweden), et al. (2024) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezae355 · Cited by 129
Domenig, O., Manzel, A., Grobe, N., Königshausen, E., Kaltenecker, C. C., Kovarik, J. J., Stegbauer, J., Gurley, S. B., van Oyen, D., Antlanger, M., et al. (2016) · Scientific Reports · doi:10.1038/srep33678 · Cited by 102
“Since the combined pharmacologic blockade of NEP and AT1-receptor with LCZ696 showed significantly reduced overall mortality in the heart failure trial PARADIGM-HF 19 , we were especially interested in the involvement of NEP in renal alternative RAS activation.”
Rao, V. N., Murray, E. M., Butler, J., Cooper, L. B., Cox, Z. L., Fiuzat, M., Green, J. B., Lindenfeld, J., McGuire, D. K., Nassif, M. E., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.064 · Cited by 106
2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure: Executive Summary
Heidenreich, P. A., Bozkurt, B., Aguilar, D. A., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A. M., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.02.009 · Cited by 118
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
van de Bovenkamp, A. A., van Rossum, A. C., & Handoko, M. L. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2000284 · Cited by 98
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Greenlaw, N., Lefkowitz, M. P., Rizkala, A. R., Shi, V. C., Rouleau, J. L., Solomon, S. D., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu455 · Cited by 106
“As such, they are well suited for comparison with PARADIGM-HF.”
BackgroundMethodInfluentialSelf-citationGandhi, S., Mosleh, W., Sharma, U. C., Demers, C., Farkouh, M. E., & Schwalm, J.-D. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.05.011 · Cited by 116
Polhemus, D. J., Trivedi, R. K., Gao, J., Li, Z., Scarborough, A. L., Goodchild, T. T., Varner, K. J., Xia, H., Smart, F. W., Kapusta, D. R., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.056 · Cited by 97
Renin–Angiotensin–Aldosterone System and Immunomodulation: A State-of-the-Art Review
Laghlam, D., Jozwiak, M., & Nguyen, L. S. (2021) · Cells · doi:10.3390/cells10071767 · Cited by 96
Semaglutide and NT-proBNP in Obesity-Related HFpEF
Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Kitzman, D. W., Shah, S. J., Verma, S., Jensen, T. J., Einfeldt, M. N., Liisberg, K., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.04.022 · Cited by 95
Docherty, K. F., Jhund, P. S., Anand, I., Bengtsson, O., Böhm, M., de Boer, R. A., DeMets, D. L., Desai, A. S., Drozdz, J., Howlett, J., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.047480 · Cited by 95
Self-citation‘Hearts and minds’: association, causation and implication of cognitive impairment in heart failure
Cannon, J. A., McMurray, J. J. V., & Quinn, T. J. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0106-5 · Cited by 105
“This trial was recently stopped for benefit of LCZ696 over enalapril [71].”
BackgroundSelf-citationStatistical Controversies in Reporting of Clinical Trials
Pocock, S., McMurray, J. J. V., & Collier, T. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.023 · Cited by 101
Self-citationLan, N. S. R., Fegan, P. G., Yeap, B. B., & Dwivedi, G. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12505 · Cited by 106
“Notably, the EMPEROR-Preserved trial (NCT03057951) is currently aiming to recruit 6000 participants with chronic HFpEF, whilst the EMPEROR-Reduced trial (NCT03057977) is aiming to recruit 2850 participants with chronic HFrEF.”
BackgroundInfluentialButler, J., McMullan, C. J., Anstrom, K. J., Barash, I., Bonaca, M. P., Borentain, M., Corda, S., Ezekowitz, J. A., Felker, G. M., Gates, D. F., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01665-4 · Cited by 121
Natriuretic Peptides and Cardiometabolic Health
Gupta, D. K., & Wang, T. J. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-0589 · Cited by 95
Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease
Bernardi, S., Michelli, A., Zuolo, G., Candido, R., & Fabris, B. (2016) · Journal of Diabetes Research · doi:10.1155/2016/8917578 · Cited by 104
Engineering an Amine Transaminase for the Efficient Production of a Chiral Sacubitril Precursor
Novick, S. J., Dellas, N., Garcia, R., Ching, C., Bautista, A., Homan, D., Alvizo, O., Entwistle, D. A., Kleinbeck, F., Schlama, T., et al. (2021) · ACS Catalysis · doi:10.1021/acscatal.0c05450 · Cited by 94
Signaling cascades in the failing heart and emerging therapeutic strategies
He, X., Du, T., Long, T., Liao, X., Dong, Y., & Huang, Z. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00972-6 · Cited by 113
“Sacubitril–valsartan provided additive survival benefits for chronic heart failure patients by further inhibiting the neutral endopeptidase neprilysin.(15) The great success of sodium–glucose cotransporter 2 inhibitors in chronic heart failure(16,17) originated from an unexpected observation of heart failure risk redu…”
BackgroundVodovar, N., Seronde, M., Laribi, S., Gayat, É., Lassus, J. P. E., Januzzi, J. L., Boukef, R., Nouira, S., Manivet, P., Samuel, J., et al. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2015.03.011 · Cited by 101
“These have included the infusion of either recombinant (e.g., nesiritide [14] or ularitide [15]) or synthetic NPs (e.g., vasonatrin [16] or CD-NP [17]) and inhibition of the NPdegrading neprilysin (also known as neutral endopeptidase) in combination either with inhibition of the angiotensin-converting enzyme (18) or a…”
BackgroundSuematsu, Y., Jing, W., Nunes, A. C. F., Kashyap, M. L., Khazaeli, M., Vaziri, N. D., & Moradi, H. (2018) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2017.12.010 · Cited by 96
C-type natriuretic peptide co-ordinates cardiac structure and function
Moyes, A. J., Chu, S. M., Aubdool, A. A., Dukinfield, M., Margulies, K. B., Bedi, K. C., Hodivala‐Dilke, K., Baliga, R. S., & Hobbs, A. J. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz093 · Cited by 93
“…of natriuretic peptide bioactivity is thought to underpin the efficacy of the dual neprilysin/angiotensin receptor blocker LCZ696 (Entresto) in HF 43 ; indeed, since CNP is the most susceptible of the natriuretic peptides to neprilysin degradation 44 it might be postulated that this member of…”
Heart Failure Around the World
Tromp, J., Ferreira, J. P., Janwanishstaporn, S., Shah, M., Greenberg, B., Zannad, F. M., & Lam, C. S. P. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1585 · Cited by 99
Dewan, P., Jackson, A. M., Lam, C. S. P., Pfeffer, M. A., Zannad, F. M., Pitt, B., Solomon, S. D., & McMurray, J. J. V. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1776 · Cited by 94
Self-citationOptimizing Foundational Therapies in Patients With HFrEF
Sharma, A., Verma, S., Bhatt, D. L., Connelly, K. A., Swiggum, E., Vaduganathan, M., Zieroth, S. R., & Butler, J. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.10.018 · Cited by 107
Yancy, C. W., Jessup, M. L., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2016) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2016.07.001 · Cited by 99
Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure
Sangaralingham, L. R., Sangaralingham, S. J., Shah, N. D., Yao, X., & Dunlay, S. M. (2018) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.004302 · Cited by 99
Jing, W., Vaziri, N. D., Nunes, A. C. F., Suematsu, Y., Farzaneh, T., Khazaeli, M., & Moradi, H. (2017) · PubMed Central · Cited by 91
Fluid Management In Patients With Chronic Heart Failure
Pellicori, P., Kaur, K., & Clark, A. L. (2015) · Cardiac failure review · doi:10.15420/cfr.2015.1.2.90 · Cited by 109
Costs and healthcare utilisation of patients with heart failure in Spain
Escobar, C., Varela, L. F., Palacios, B., Capel, M., Sicras, A., Sicras, A., Hormigo, A., Arroyo, R. A., Manito, N., & Botana, M. (2020) · BMC Health Services Research · doi:10.1186/s12913-020-05828-9 · Cited by 100
Wideqvist, M., Cui, X., Magnusson, C., Schaufelberger, M., & Fu, M. L. X. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13221 · Cited by 92
“Adherence to HF treatment is crucial because specific medication reduce both mortality and morbidity.(25,26) Targeting specific individuals at risk”
BackgroundIncidence and Outcomes of Pneumonia in Patients With Heart Failure
Shen, L., Jhund, P. S., Anand, I. S., Bhatt, A. S., Desai, A. S., Maggioni, A. P., Martínez, F. A., Pfeffer, M. A., Rizkala, A. R., Rouleau, J. L., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.03.001 · Cited by 113
Self-citationIschaemic cardiomyopathy: pathophysiology, assessment and the role of revascularisation
Briceno, N. I., Schuster, A., Lumley, M., & Perera, D. (2016) · Heart · doi:10.1136/heartjnl-2015-308037 · Cited by 91
van de Wouw, J., Broekhuizen, M., Sorop, O., Joles, J. A., Verhaar, M. C., Duncker, D. J., Danser, A. H. J., & Merkus, D. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01108 · Cited by 106
Pieske, B., Patel, M. J., Westerhout, C. M., Anstrom, K. J., Butler, J., Ezekowitz, J., Hernandez, A. F., Koglin, J., Lam, C. S. P., Ponikowski, P., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1664 · Cited by 90
Beggs, S. A. S., Jhund, P. S., Jackson, C. E., McMurray, J. J. V., & Gardner, R. S. (2018) · Heart · doi:10.1136/heartjnl-2016-310850 · Cited by 90
Self-citationColantuoni, E., Scharfstein, D. O., Wang, C., Hashem, M. D., Leroux, A., Needham, D. M., & Girard, T. D. (2018) · BMJ · doi:10.1136/bmj.j5748 · Cited by 90
Butt, J. H., Fosbøl, E. L., Gerds, T. A., Andersson, C., McMurray, J. J. V., Petrie, M. C., Gustafsson, F., Madelaire, C., Kristensen, S. L., Gislason, G., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1800 · Cited by 99
Self-citationKobalava, Z. D., Kotovskaya, Y. V., Валерьевич, А. О., Павликова, Е. П., Моисеев, В. С., Albrecht, D., Chandra, P., Ayalasomayajula, S. P., PRESCOTT, M. F., Pal, P., et al. (2016) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12183 · Cited by 90
Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions
Lund, L. H., Oldgren, J., & James, S. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0325-0 · Cited by 89
Ishii, M., Kaikita, K., Sato, K., Sueta, D., Fujisue, K., Arima, Y., Oimatsu, Y., Mitsuse, T., Onoue, Y., Araki, S., et al. (2017) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2017.08.001 · Cited by 89
“A previous randomized clinical trial showed that LCZ696 significantly reduces the risks of cardiovascular death and hospitalization for HF with reduced ejection fraction than enalapril, resulting in a new treatment option for chronic HF beyond the RAAS blockade (5).”
BackgroundMethodBNP as a Major Player in the Heart-Kidney Connection
Okamoto, R., Ali, Y. M., Hashizume, R., 昇, 鈴., & Ito, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143581 · Cited by 102
Sacubitril/valsartan in the treatment of systemic right ventricular failure
Zandstra, T. E., Nederend, M., Jongbloed, M. R. M., Kiès, P., Vliegen, H. W., Bouma, B. J., Tops, L. F., Schalij, M. J., & Egorova, A. D. (2021) · Heart · doi:10.1136/heartjnl-2020-318074 · Cited by 95
Isaza, N., Calvachi, P., Raber, I., Liu, C.-L., Bellows, B. K., Hernandez, I., Shen, C., Gavin, M. C., Garan, A. R., & Kazi, D. S. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.14501 · Cited by 89
Prevalence, outcomes and costs of a contemporary, multinational population with heart failure
Norhammar, A., Bodegård, J., Vanderheyden, M., Tangri, N., Karasik, A., Maggioni, A. P., Sveen, K. A., Taveira‐Gomes, T., Botana, M., Hunziker, L., et al. (2023) · Heart · doi:10.1136/heartjnl-2022-321702 · Cited by 129
Januzzi, J. L., Butler, J., Fombu, E., Maisel, A. S., McCague, K., Piña, I. L., PRESCOTT, M. F., Riebman, J. B., & Solomon, S. D. (2018) · American Heart Journal · doi:10.1016/j.ahj.2017.12.021 · Cited by 96
“Subgroups represent patients for whom data on sacubitril/ valsartan are lacking, including (1) patients with HFrEF and “low” NTproBNP concentration (b600 pg/mL if not hospitalized or b400 pg/mL if hospitalized) or “low” BNP concentration (b150 pg/mL if not hospitalized or b100 pg/mL if hospitalized) at baseline(21); (…”
MethodSelf-citationPerera, D., Clayton, T. C., Petrie, M. C., Greenwood, J. P., O’Kane, P. D., Evans, R., Sculpher, M., McDonagh, T. A., Gershlick, A., de Belder, M., et al. (2018) · JACC Heart Failure · doi:10.1016/j.jchf.2018.01.024 · Cited by 100
“4 Introduction The prevalence of heart failure (HF) due to left ventricular (LV) systolic dysfunction is increasing (1) and ischemic cardiomyopathy (ICM) accounts for approximately 60% of all HF cases(2, 3).”
Bavendiek, U., Berliner, D., Dávila, L. A., Schwab, J., Maier, L. S., Philipp, S., Rieth, A. J., Westenfeld, R., Piorkowski, C., Weber, K., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1452 · Cited by 97
Medical Therapies for Heart Failure With Preserved Ejection Fraction
Kjeldsen, S. E., von Lueder, T. G., Smiseth, O. A., Wachtell, K., Mistry, N., Westheim, A. S., Hopper, I., Julius, S., Pitt, B., Reid, C. M., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.14057 · Cited by 98
“The PARAGON-HF trial (Efficacy and Safety of LCZ696 Compared With Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction) was a randomized, double-blind trial that evaluated the safety and efficacy of a dual-acting RAAS blocker (an ARNI) versus a stand-alone ARB on the composi…”
ResultInfluential2020 Clinical practice guidelines for Chronic heart failure
Russian Society of Cardiology (2020) · Russian Journal of Cardiology · doi:10.15829/29/1560-4071-2020-4083 · Cited by 88
DeVore, A. D., Braunwald, E., Morrow, D. A., Duffy, C. I., Ambrosy, A. P., Chakraborty, H., McCague, K., Rocha, R., Velazquez, E. J., & for the PIONEER-HF Investigators (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2019.4665 · Cited by 87
Guiraud, D., Andreu, D., Bonnet, S., Carrault, G., Couderc, P., Hagège, A., Henry, C., Hernandez, A., Karam, N., Le Rolle, V., et al. (2016) · Journal of Neural Engineering · doi:10.1088/1741-2560/13/4/041002 · Cited by 87
“…consist of single or combined pharmacological approaches: diuretics (Marvin, 1927) , beta-blockers and ACE inhibitors (angiotensin-converting-enzyme) (Ho et al., 2014) , Ivabradine to reduce heart rate (Fox et al., 2008, Swedberg et al., 2010) or a combination of molecules (McMurray et al., 2014) .”
BackgroundCardiovascular Pleiotropic Effects of Natriuretic Peptides
Forte, M., Madonna, M., Schiavon, S., Valenti, V., Versaci, F., Biondi‐Zoccai, G., Frati, G., & Sciarretta, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163874 · Cited by 95
Lee, S., Oh, J., Kim, H., Ha, J., Chun, K., Lee, C. J., Park, S., Lee, S., & Kang, S. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12659 · Cited by 87
“Sacubitril/valsartan (SV) reduced heart failure (HF) hospitalization and cardiovascular mortality compared with angiotensin-converting enzyme inhibitor (ACE-I), enalapril in the Prospective Comparison of ARNI with ACE-I to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial.(1) But…”
BackgroundCyclic GMP and PKG Signaling in Heart Failure
Numata, G., & Takimoto, E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.792798 · Cited by 105
Edema formation in congestive heart failure and the underlying mechanisms
Abassi, Z. A., Khoury, E. E., Karram, T., & Aronson, D. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.933215 · Cited by 141
“When given with ACEi or diuretics, β-blockers have been shown to reduce mortality and morbidity in patients with HFrEF (267).”
BackgroundInfluentialHandelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., Cherney, D. Z. I., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155931 · Cited by 103
Heart failure: assessment of the global economic burden
Darvish, M., Shakoor, A., Feyz, L., Schaap, J., Mieghem, N. M. V., de Boer, R. A., Brugts, J. J., & van der Boon, R. M. A. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf323 · Cited by 108
“8–10 As such, there is a clear rationale for an updated assessment of the annual, global economic burden associated with HF.”
Sarzani, R., Giulietti, F., Di Pentima, C., Giordano, P., & Spannella, F. (2020) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00189.2020 · Cited by 86
The cGMP system: components and function
Hofmann, F. B. (2019) · Biological Chemistry · doi:10.1515/hsz-2019-0386 · Cited by 88
Mansi, R., Nock, B. A., Dalm, S. U., Busstra, M. B., van Weerden, W. M., & Μάινα, Θ. (2021) · Cancers · doi:10.3390/cancers13225766 · Cited by 97
Role of Cardiac Natriuretic Peptides in Heart Structure and Function
Sarzani, R., Allevi, M., Pentima, C. D., Schiavi, P., Spannella, F., & Giulietti, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214415 · Cited by 102
Current State of Pediatric Heart Failure
Das, B. B. (2018) · Children · doi:10.3390/children5070088 · Cited by 89
“The PARADIGM-HF (Prospective comparison of angiotensin receptor antagonist (Valsartan) and neprilysin inhibitor (Sacubitril) with angiotensin converting enzyme inhibitor (Enalapril) to determine impact on Global Mortality and Morbidity in Heart Failure) trial, has demonstrated that Sacubitril/Valsartan is superior to…”
MethodBouabdallaoui, N., Claggett, B., Zile, M. R., McMurray, J. J. V., O'Meara, E., Packer, M., Prescott, M. F., Swedberg, K., Solomon, S. D., Rouleau, J. L., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1301 · Cited by 83
Self-citationBorow, K. M., Yaroshinsky, A., Greenberg, B., & Perin, E. C. (2019) · Circulation Research · doi:10.1161/circresaha.119.314951 · Cited by 94
Metadata
- Authors
- McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., & Zile, M. R.
- Affiliations
- Brigham and Women's Hospital (US)
- The University of Texas Southwestern Medical Center (US)
- Montreal Heart Institute (CA)
- Imperial College London (GB)
- Medical University of South Carolina (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-09-11
- Volume
- 371
- Issue
- 11
- Pages
- 993-1004
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2113698123
- Cited by
- 6,957
- References
- 30
- Citations by year
- 2026: 432 · 2025: 599 · 2024: 634 · 2023: 711 · 2022: 725 · 2021: 758 · 2020: 750 · 2019: 613 · 2018: 482 · 2017: 484 · 2016: 411 · 2015: 296 · 2014: 41
- FWCI
- 281.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Keele Research Repository (Keele University) (submittedVersion, cc-by)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- angiotensin receptor-neprilysin inhibition, sacubitril/valsartan, enalapril, heart failure with reduced ejection fraction, cardiovascular mortality, heart failure hospitalization, heart failure symptoms, hypotension, angiotensin II receptor blockade, ACE inhibitors, renin-angiotensin system, heart failure prognosis, heart failure with preserved ejection fraction
- MeSH terms
- Valsartan, Aged, Aminobutyrates, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Double-Blind Method, Drug Combinations, Enalapril, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Stroke Volume, Tetrazoles, Neprilysin, Kaplan-Meier Estimate, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.